Chronic obstructive pulmonary disease (COPD) Trials in Witten, Germany
Conditions / Chronic obstructive pulmonary disease (COPD) / Witten, Germany
Chronic obstructive pulmonary disease (COPD) is a medical condition with active clinical research programs worldwide.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01908140 | Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT01782326 | QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations) | COMPLETED | PHASE3 |
| NCT05573464 | A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT00313209 | Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127) | COMPLETED | PHASE3 |
| NCT00821093 | Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT01462942 | Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination | COMPLETED | PHASE3 |
| NCT05492877 | An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. | COMPLETED | PHASE2 |
| NCT00722267 | European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients | COMPLETED | — |
| NCT01202188 | A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT07082738 | A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | RECRUITING | PHASE2 |